Author
Listed:
- Jichao Sun
(University of Wisconsin-Madison)
- Jared Carlson-Stevermer
(University of Wisconsin-Madison
University of Wisconsin-Madison)
- Utpal Das
(University of California)
- Minjie Shen
(University of Wisconsin-Madison)
- Marion Delenclos
(Mayo Clinic Jacksonville)
- Amanda M. Snead
(Columbia University Medical Center)
- So Yeon Koo
(Columbia University Medical Center)
- Lina Wang
(University of Wisconsin-Madison)
- Dianhua Qiao
(University of Wisconsin-Madison)
- Jonathan Loi
(University of Wisconsin-Madison)
- Andrew J. Petersen
(University of Wisconsin-Madison)
- Michael Stockton
(University of Wisconsin-Madison)
- Anita Bhattacharyya
(University of Wisconsin-Madison)
- Mathew V. Jones
(University of Wisconsin-Madison)
- Xinyu Zhao
(University of Wisconsin-Madison
University of Wisconsin-Madison)
- Pamela J. McLean
(Mayo Clinic Jacksonville)
- Andrew A. Sproul
(Columbia University Medical Center
Columbia University Medical Center)
- Krishanu Saha
(University of Wisconsin-Madison
University of Wisconsin-Madison)
- Subhojit Roy
(University of Wisconsin-Madison
University of Wisconsin-Madison)
Abstract
CRISPR/Cas9 guided gene-editing is a potential therapeutic tool, however application to neurodegenerative disease models has been limited. Moreover, conventional mutation correction by gene-editing would only be relevant for the small fraction of neurodegenerative cases that are inherited. Here we introduce a CRISPR/Cas9-based strategy in cell and animal models to edit endogenous amyloid precursor protein (APP) at the extreme C-terminus and reciprocally manipulate the amyloid pathway, attenuating APP-β-cleavage and Aβ production, while up-regulating neuroprotective APP-α-cleavage. APP N-terminus and compensatory APP-homologues remain intact, with no apparent effects on neurophysiology in vitro. Robust APP-editing is seen in human iPSC-derived neurons and mouse brains with no detectable off-target effects. Our strategy likely works by limiting APP and BACE-1 approximation, and we also delineate mechanistic events that abrogates APP/BACE-1 convergence in this setting. Our work offers conceptual proof for a selective APP silencing strategy.
Suggested Citation
Jichao Sun & Jared Carlson-Stevermer & Utpal Das & Minjie Shen & Marion Delenclos & Amanda M. Snead & So Yeon Koo & Lina Wang & Dianhua Qiao & Jonathan Loi & Andrew J. Petersen & Michael Stockton & An, 2019.
"CRISPR/Cas9 editing of APP C-terminus attenuates β-cleavage and promotes α-cleavage,"
Nature Communications, Nature, vol. 10(1), pages 1-11, December.
Handle:
RePEc:nat:natcom:v:10:y:2019:i:1:d:10.1038_s41467-018-07971-8
DOI: 10.1038/s41467-018-07971-8
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:10:y:2019:i:1:d:10.1038_s41467-018-07971-8. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.